

### EntrepreneurShares Series Trust<sup>TM</sup>

## **ERShares Global Entrepreneurs (ENTIX)**

### **ERShares US Small Cap (IMPAX)**

### **Semi-Annual Report**

### December 31, 2023

175 Federal Street Suite 875 Boston, MA 02110 Toll Free: 877-271-8811

# SCHEDULE OF INVESTMENTS SUMMARY TABLE<sup>(1)</sup> as of December 31, 2023 (Unaudited)

Sector	% of Net Assets
Technology	34.23%
Health Care	18.90%
Communications	15.35%
Consumer Discretionary	11.30%
Financials	4.76%
Industrials	3.41%
Energy	3.31%
Money Market Funds	2.29%
Real Estate	2.23%
Consumer Staples	2.23%
Materials	1.92%
Other Assets in Excess of Liabilities	0.07%
	100.00%

<sup>(1)</sup> Fund holdings and sector allocations are subject to change at any time and are not recommendations to buy or sell any security.

# SCHEDULE OF INVESTMENTS SUMMARY TABLE<sup>(1)</sup> as of December 31, 2023 (Unaudited)

Sector	% of Net Assets
Technology	37.51%
Health Care	29.54%
Consumer Discretionary	12.12%
Communications	5.10%
Financials	4.54%
Industrials	3.92%
Energy	2.97%
Consumer Staples	1.49%
Money Market Funds	1.11%
Real Estate	0.98%
Materials	0.64%
Other Assets in Excess of Liabilities	0.08%
	100.00%

<sup>(1)</sup> Fund holdings and sector allocations are subject to change at any time and are not recommendations to buy or sell any security.

### SCHEDULE OF INVESTMENTS

December 31, 2023 (Unaudited)

	Shares	Fair Value
Common Stocks — 97.64% Argentina — 2.21% Consumer Discretionary — 2.21% MercadoLibre, Inc. <sup>(a)</sup> Total Argentina	747	<u>\$ 1,173,940</u> 1,173,940
Australia — 4.70% Communications — 1.19% SEEK Ltd.	34,715	632,451
Consumer Discretionary — 0.72% Flight Centre Travel Group Ltd.	27,630	383,415
Health Care — 1.18% Telix Pharmaceuticals Ltd. <sup>(a)</sup>	91,046	625,507
Materials — 0.31% Fortescue Metals Group Ltd.	8,401	166,165
Technology — 1.30% Technology One Ltd. WiseTech Global Ltd. Total Australia	33,491 6,656	350,843 341,918 692,761 2,500,299
Bermuda — 0.18% Consumer Discretionary — 0.18% Luk Fook Holdings International Ltd. Total Bermuda	35,753	<u> </u>
Canada — 4.51% Communications — 3.24% Shopify, Inc., Class A <sup>(a)</sup>	22,062	1,718,630
Consumer Discretionary — 0.71% Linamar Corp. Spin Master Corp.	4,450 6,344	215,015 <u>166,911</u> 381,926
Materials — 0.05% First Majestic Silver Corp.	4,174	25,612

### **SCHEDULE OF INVESTMENTS (Continued)**

December 31, 2023 (Unaudited)

	Shares	Fair Value
Common Stocks (continued)		
Canada (Continued) Real Estate — 0.26%		
FirstService Corp.	383	\$ 62,047
Mainstreet Equity Corp. <sup>(a)</sup>	674	74,279
		136,326
Technology — 0.25%		
Topicus.com, Inc. <sup>(a)</sup>	2,013	135,581
Total Canada		2,398,075
Cayman Islands — 2.68%		
Consumer Discretionary — 1.28%		
NagaCorp Ltd. <sup>(a)</sup>	667,144	262,294
Yadea Group Holdings Ltd.	236,140	414,910
		677,204
Financials — 0.17%	225 005	02.082
Value Partners Group Ltd.	335,995	92,082
Health Care — 0.03%		
Essex Bio-Technology Ltd.	47,318	15,089
Industrials — 0.82%	(1.0.42)	122 510
Full Truck Alliance Company Ltd ADR <sup>(a)</sup>	61,843	433,519
Materials — 0.38%		
Xinyi Glass Holdings Ltd.	181,294	203,384
Total Cayman Islands		1,421,278
China — 2.99%		
Communications — 0.36% Weimob, Inc. <sup>(a)</sup>	513,712	189,471
weiniob, nic.	515,712	109,471
Consumer Discretionary — 0.37%		
Bosideng International Holdings, Ltd.	439,635	197,619
Financials — 1.54%		0.1.5.705
Futu Holdings Ltd ADR <sup>(a)</sup>	14,946	816,500
Health Care — 0.42%		
Sino Biopharmaceutical Ltd.	499,967	222,178
1		

### **SCHEDULE OF INVESTMENTS (Continued)**

December 31, 2023 (Unaudited)

	Shares	Fair Value
Common Stocks (continued) China (Continued) Technology — 0.30% Kingsoft Corp. Ltd. Total China	51,538	<u>\$ 159,065</u> 
Denmark — 0.49% Health Care — 0.49% Genmab A/S <sup>(a)</sup> Total Denmark	819	<u>261,403</u> 261,403
France — 0.45% Communications — 0.14% Ubisoft Entertainment S.A. <sup>(a)</sup>	2,880	73,478
Industrials — 0.31% Teleperformance SE Total France	1,124	<u>    163,860</u> 237,338
Germany — 0.18% Communications — 0.18% Delivery Hero S.E. <sup>(a)</sup> Total Germany	3,490	<u>96,362</u> <u>96,362</u>
Hong Kong — 0.77% Industrials — 0.77% Techtronic Industries Co. Ltd. Total Hong Kong	34,252	<u>408,162</u> 408,162
Ireland — 1.36% Industrials — 1.36% Cimpress PLC <sup>(a)</sup> Total Ireland	9,048	<u> </u>
Isle Of Man — 0.27% Consumer Discretionary — 0.27% Entain PLC Total Isle Of Man	11,451	<u>    145,132</u> <u>    145,132</u>
Israel — 4.69% Communications — 2.50% Wix.com Ltd. <sup>(a)</sup>	10,770	1,324,925

### SCHEDULE OF INVESTMENTS (Continued)

December 31, 2023 (Unaudited)

	Shares	Fair Value
Common Stocks (continued) Israel (Continued)		
Energy — 1.37% SolarEdge Technologies, Inc. <sup>(a)</sup>	7,800	<u>\$ 730,080</u>
Technology — 0.82% Monday.com Ltd. <sup>(a)</sup> Total Israel	2,333	<u>438,161</u> 2,493,166
Italy — 0.14% Communications — 0.14% Digital Bros SpA Total Italy	6,448	76,525 76,525
Japan — 0.37% Communications — 0.37% GMO internet, Inc. Total Japan	10,774	<u>    195,863</u> <u>    195,863</u>
Jersey — 0.84% Communications — 0.84% Gambling.com Group Ltd. <sup>(a)</sup> Total Jersey	46,080	<u>    449,280</u> 449,280
Luxembourg — 1.15% Communications — 1.15% Spotify Technology SA <sup>(a)</sup> Total Luxembourg	3,249	<u>610,520</u> 610,520
Netherlands — 0.17% Technology — 0.17% Adyen NV - ADR <sup>(a)</sup> Total Netherlands	7,109	<u> </u>
Singapore — 1.67% Communications — 1.04% Sea Ltd ADR <sup>(a)</sup>	13,707	555,134
Consumer Staples — 0.63% Wilmar International Ltd. Total Singapore	123,149	<u>333,148</u> 888,282

### **SCHEDULE OF INVESTMENTS (Continued)**

December 31, 2023 (Unaudited)

	Shares	Fair Value
Common Stocks (continued) Sweden — 3.14%		
Communications — 0.89%		
Embracer Group A.B. <sup>(a)</sup>	174,586	<u>\$ 473,598</u>
Consumer Discretionary — 0.96%		
Evolution Gaming Group A.B.	4,269	508,940
Financials — 1.17%		
EQT A.B.	22,013	622,139
Technology — 0.12%		
Sinch A.B. <sup>(a)</sup>	17,102	63,615
Total Sweden		1,668,292
Switzerland — 2.45%		
Consumer Discretionary — 0.29%		
Cie Financiere Richemont SA	1,112	153,034
Financials — 1.17%		
Partners Group Holding AG	433	624,470
Health Care — 0.99%		
CRISPR Therapeutics AG <sup>(a)(b)</sup>	8,374	524,212
Total Switzerland		1,301,716
United Kingdom — 1.75%		
Financials — 0.71%		
Hargreaves Lansdown PLC	40,579	379,702
Health Care — 0.68%		
Hikma Pharmaceuticals PLC	15,836	361,162
Materials — 0.36%		
Antofagasta PLC	8,908	190,724
Total United Kingdom		931,588
United States — 60.48%		
Communications $-3.31\%$	<b>Z</b> (22)	
Airbabat, Inc., Class A <sup>(a)</sup>	5,002	680,972
Alphabet, Inc., Class A <sup>(a)</sup> Trade Desk, Inc. (The), Class A <sup>(a)</sup>	3,617 8,017	505,259 576,903
Hade Desk, Ille, Class A	0,017	1,763,134
		1,703,134

### **SCHEDULE OF INVESTMENTS (Continued)**

December 31, 2023 (Unaudited)

	Shares	Fair Value
Common Stocks (continued)		
United States (continued)		
Consumer Discretionary — 4.31%		<b>•</b> • • • • • •
Chipotle Mexican Grill, Inc. <sup>(a)</sup>	147	\$ 336,183
Etsy, Inc. <sup>(a)</sup>	17,644	1,430,046
Wayfair, Inc., Class A <sup>(a)</sup>	8,548	527,412
Consumer Stepler 1 (00/		2,293,641
Consumer Staples — 1.60%	5 992	940 153
e.l.f. Beauty, Inc. <sup>(a)</sup>	5,883	849,152
Energy — 1.94%		
Enphase Energy, Inc. <sup>(a)</sup>	3,942	520,896
Valero Energy Corp.	3,910	508,300
		1,029,196
Health Care — 15.11%		
Exact Sciences Corp. <sup>(a)</sup>	24,619	1,821,314
Globus Medical, Inc., Class A <sup>(a)</sup>	4,834	257,604
Madrigal Pharmaceuticals, Inc. <sup>(a)</sup>	3,205	741,573
Masimo Corp. <sup>(a)</sup>	7,109	833,246
Natera, Inc. <sup>(a)</sup>	10,949	685,845
Penumbra, Inc. <sup>(a)</sup>	3,393	853,475
ResMed, Inc.	4,585	788,712
Shockwave Medical, Inc. <sup>(a)</sup>	3,653	696,116
Supernus Pharmaceuticals, Inc. <sup>(a)</sup>	16,069	465,037
Twist Bioscience Corp. <sup>(a)</sup>	24,174	891,053
		8,033,975
Industrials — 0.15%		
Veralto Corp.	958	78,805
Materials — 0.82%		
Mosaic Co. (The)	6,691	239,069
	1,684	198,880
Steel Dynamics, Inc.	1,084	
Real Estate — 1.97%		437,949
	8,275	1 040 022
Alexandria Real Estate Equities, Inc.	8,275	1,049,022
Technology — 31.27%		
Affirm Holdings, Inc. <sup>(a)(b)</sup>	29,486	1,448,942
Arista Networks, Inc. <sup>(a)</sup>	3,405	801,912
Bentley Systems, Inc.	5,757	300,400
Bill.com Holdings, Inc. <sup>(a)</sup>	12,806	1,044,842
Diff.com Holdings, file.	12,800	1,044,042

### **SCHEDULE OF INVESTMENTS (Continued)**

December 31, 2023 (Unaudited)

	Shares	Fair Value
Common Stocks (continued)		
United States (continued)		
Technology (continued)		
Block, Inc., Class A <sup>(a)</sup>	21,111	\$ 1,632,936
Cloudflare, Inc., Class A <sup>(a)</sup>	9,924	826,272
Crowdstrike Holdings, Inc., Class A <sup>(a)</sup>	1,230	314,044
FleetCor Technologies, Inc. <sup>(a)</sup>	1,205	340,545
Microchip Technology, Inc.	7,015	632,613
MongoDB, Inc. <sup>(a)</sup>	1,971	805,843
Monolithic Power Systems, Inc.	718	452,900
NVIDIA Corp.	1,019	504,629
Palo Alto Networks, Inc. <sup>(a)</sup>	1,644	484,783
Paycom Software, Inc.	2,633	544,294
Pegasystems, Inc.	18,815	919,301
Salesforce, Inc. <sup>(a)</sup>	2,011	529,175
Super Micro Computer, Inc. <sup>(a)</sup>	1,850	525,881
Toast, Inc., Class A <sup>(a)</sup>	101,200	1,847,912
Twilio, Inc., Class A <sup>(a)</sup>	19,132	1,451,546
UiPath, Inc., Class A <sup>(a)</sup>	26,441	656,794
Veeva Systems, Inc., Class A <sup>(a)</sup>	2,924	562,928
		16,628,492
Total United States		32,163,366
Total Common Stocks (Cost \$47,410,225)		51,917,200
Money Market Funds — 6.24%		
Fidelity Investments Money Market Treasury Only Portfolio, Class I, 5.24% <sup>(c)</sup>	1,217,067	1,217,067
Invesco Government & Agency Portfolio, Class I, 5.28% <sup>(c)(d)</sup>	2,098,487	2,098,487
Total Money Market Funds (Cost \$3,315,554)		3,315,554
Total Investments — 103.88% (Cost \$50,725,779)		\$ 55,232,754
Liabilities in Excess of Other Assets — (3.88)%		(2,061,156)
Net Assets — 100.00%		\$ 53,171,598

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> All or a portion of the security is on loan as of December 31, 2023. The total value of the securities on loan as of December 31, 2023 was \$1,973,043.

<sup>(c)</sup> Rate disclosed is the seven day effective yield as of December 31, 2023.

<sup>(d)</sup> All or a portion of this security was purchased with cash proceeds from securities lending. Total collateral had a value of \$2,098,487. See Note 2.

ADR - American Depositary Receipt

### SCHEDULE OF INVESTMENTS December 31, 2023 (Unaudited)

	Shares	Fair Value
Common Stocks — 98.81%		
Communications — 5.10%		
Cargurus, Inc. <sup>(a)</sup>	30,764	\$ 743,258
Eventbrite, Inc., Class A <sup>(a)</sup>	71,753	599,855
Match Group, Inc. <sup>(a)</sup>	22,901	835,887
Shutterstock, Inc.	19,781	955,026
Yelp, Inc. <sup>(a)</sup>	16,702	790,673
		3,924,699
Consumer Discretionary — 12.12%		
1-800-Flowers.com, Inc., Class A <sup>(a)</sup>	43,428	468,154
AutoNation, Inc. <sup>(a)</sup>	5,449	818,331
Chewy, Inc. <sup>(a)</sup>	35,495	838,747
Etsy, Inc. <sup>(a)</sup>	12,768	1,034,845
OneWater Marine, Inc. <sup>(a)</sup>	20,369	688,269
RealReal, Inc. (The) <sup>(a)</sup>	202,202	406,426
RH <sup>(a)</sup>	3,113	907,377
Rush Street Interactive, Inc. <sup>(a)</sup>	175,001	785,755
Shake Shack, Inc., Class A <sup>(a)</sup>	9,729	721,113
Signet Jewelers Ltd.	7,187	770,878
Thor Industries, Inc.	2,596	306,977
Wayfair, Inc., Class A <sup>(a)</sup>	15,069	929,757
XPEL, Inc. <sup>(a)</sup>	12,208	657,401
		9,334,030
Consumer Staples — 1.49%		
e.l.f. Beauty, Inc. <sup>(a)</sup>	5,647	815,088
Five Below, Inc. <sup>(a)</sup>	1,565	333,595
,	,	1,148,683
Energy — 2.97%		,
Ameresco, Inc., Class A <sup>(a)</sup>	31,003	981,865
Liberty Energy, Inc., Class A	72,046	1,306,914
		2,288,779
Financials — 4.54%		
Grid Dynamics Holdings, Inc. <sup>(a)</sup>	65,716	875,994
Live Oak Bancshares, Inc.	12,582	572,481
Preferred Bank	5,735	418,942
Robinhood Markets, Inc., Class A <sup>(a)</sup>	78,567	1,000,944
Trupanion, Inc. <sup>(a)(b)</sup>	20,530	626,370
		3,494,731
Health Care — 29.54%		
10X Genomics, Inc., Class A <sup>(a)</sup>	23,594	1,320,320
ACADIA Pharmaceuticals, Inc. <sup>(a)</sup>	9,686	303,269
Alector, Inc. <sup>(a)</sup>	102,381	817,000

### SCHEDULE OF INVESTMENTS (Continued)

December 31, 2023 (Unaudited)

AAON, Inc. $7,129$ $526,619$ Allegiant Travel Co. $3,112$ $257,082$ Archer Aviation, Inc., Class A <sup>(a)(b)</sup> $126,984$ $779,682$ Enovis Corp. <sup>(a)</sup> $5,446$ $305,085$ ESAB Corp. $8,572$ $742,507$ Forrester Research, Inc. <sup>(a)</sup> $4,946$ $132,602$ Wheels Up Experience, Inc. <sup>(a)</sup> $79,930$ $274,160$ $3,017,737$ $3,017,737$		Shares	Fair Value
Health Care (continued)       15,304       \$ 946,552         Arcus Biosciences, Inc. <sup>(h)</sup> 24,280       463,748         Arcus Biosciences, Inc. <sup>(h)</sup> 30,531       1,256,656         Beam Therapeutics, Inc. <sup>(h)</sup> 21,273       858,791         Castle Biosciences, Inc. <sup>(h)</sup> 21,273       858,791         Castle Biosciences, Inc. <sup>(h)</sup> 16,554       357,235         Catalyst Pharmaceuticals, Inc. <sup>(h)</sup> 59,577       1,001,489         Crus Corp. <sup>(h)</sup> 129,404       279,513         CRISPR Therapeutics AG <sup>(h)(h)</sup> 14,614       914,836         Exact Sciences Corp. <sup>(h)</sup> 19,404       272,799         Globus Medical, Inc., Class A <sup>(h)</sup> 9,522       498,368         Guardant Heath, Inc. <sup>(h)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(h)</sup> 30,30       928,786         Madrigal Pharmaceuticals, Inc. <sup>(h)</sup> 3,303       928,786         Machigae Holdings, Inc. <sup>(h)</sup> 4,992       1,155,049         Mecipaec Holdings, Inc. <sup>(h)</sup> 3,301<	Common Stocks (continued)		
Arcias Biosciences, Inc. <sup>(a)</sup> 24,280       463,748         Arvinas, Inc. <sup>(a)</sup> 30,531       1,256,656         Beam Therapeutics, Inc. <sup>(a)</sup> 21,273       858,791         Castle Biosciences, Inc. <sup>(a)</sup> 21,273       858,791         Castle Biosciences, Inc. <sup>(a)</sup> 21,273       858,791         Castly St Pharmaceuticals, Inc. <sup>(a)</sup> 59,577       1,001,489         Cerus Corp. <sup>(a)</sup> 129,404       279,513         CRISPR Therapeutics AG <sup>(a)(b)</sup> 8,694       643,182         Ginkgo Bioworks Holdings, Inc. <sup>(a)(b)</sup> \$16,449       872,799         Globus Medical, Inc., Class A <sup>(a)</sup> 9,252       498,368         Krystal Biotech, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 35,219       952,674         Krystal Biotech, Inc. <sup>(a)</sup> 35,219       952,674         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 35,219       952,674         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 35,300       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 3,303       928,786         Select Medical Holdings, Inc. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup>			
Arvinas, Inc. <sup>(a)</sup> 30,531       1,256,656         Beam Therapeutics, Inc. <sup>(a)</sup> 21,273       858,791         Castle Biosciences, Inc. <sup>(a)</sup> 16,554       357,235         Castle Biosciences, Inc. <sup>(a)</sup> 16,554       357,235         Castle Specters, Orp. <sup>(a)</sup> 129,404       279,513         CRISPR Therapeutics AG <sup>(a)(b)</sup> 14,614       914,836         Exact Sciences Corp. <sup>(a)</sup> 8,694       643,182         Ginkgo Bioworks Holdings, Inc. <sup>(a)(b)</sup> 516,449       872,799         Globus Medical, Inc., Class A <sup>(a)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 35,219       952,674         Madrigal Pharmaceuticas, Inc. <sup>(a)</sup> 5,726       710,368         Kynstal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kynstal Biotech, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Bioscience of Corp. <sup>(a)</sup> 49,992       1,155,049         Medpace Holdings, Inc. <sup>(b)</sup> 30,30       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 30,30       928,786         Yustal Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veacyte, Inc. <sup>(b)</sup>	Amphastar Pharmaceuticals, Inc. <sup>(a)</sup>	15,304	\$ 946,552
Beam Therapeutics, Inc. <sup>(a)</sup> 8,229         223,993           Bridgebio Pharma, Inc. <sup>(a)</sup> 21,273         858,791           Castle Biosciences, Inc. <sup>(a)</sup> 16,554         357,235           Catalyst Pharmaceuticals, Inc. <sup>(a)</sup> 59,577         1,001,489           Cerus Corp. <sup>(a)</sup> 129,404         279,513           CRISPR Therapeutics AG <sup>(a)(b)</sup> 14,614         914,836           Exact Sciences Corp. <sup>(a)</sup> 8,694         643,182           Ginkgo Bioworks Holdings, Inc. <sup>(a)(b)</sup> 516,449         872,799           Globus Medical, Inc., Class A <sup>(a)</sup> 9,352         498,368           Guardant Health, Inc. <sup>(a)</sup> 35,219         952,674           Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128         796,643           Krystal Biotech, Inc. <sup>(a)</sup> 23,889         608,214           Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 23,889         608,214           Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 3,030         928,786           Reific Biosciences of California, Inc. <sup>(a)</sup> 145,574         1,428,081           Scleet Medical Holdings, Corp.         22,226         522,311           Teladoc Health, Inc. <sup>(a)</sup> 23,488         646,155           Zynex, Inc. <sup>(b)</sup> 246,455 <td>Arcus Biosciences, Inc.<sup>(a)</sup></td> <td>24,280</td> <td>463,748</td>	Arcus Biosciences, Inc. <sup>(a)</sup>	24,280	463,748
Bridgebio Pharma, Inc. <sup>(a)</sup> 21,273       858,791         Castle Biosciences, Inc. <sup>(a)</sup> 16,554       357,235         Catalyst Pharmaceuticals, Inc. <sup>(a)</sup> 59,577       1,001,489         Cerus Corp. <sup>(a)</sup> 129,404       279,513         CRISPR Therapeutics AG <sup>(a)(b)</sup> 14,614       91,483         Ginkgo Bioworks Holdings, Inc. <sup>(a)(b)</sup> 516,449       872,799         Globus Medical, Inc., Class A <sup>(a)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128       796,643         Krystal Biotech, Inc. <sup>(a)</sup> 23,889       608,214         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 4,992       1,155,049         Medpace Holdings, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 43,571       1,428,081         Veracyte, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,889       608,211         Teladoc Health, Inc. <sup>(a)</sup> 3,521       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 3,112	Arvinas, Inc. <sup>(a)</sup>	30,531	1,256,656
Caste Biosciences, Inc. <sup>(a)</sup> 16,554       357,235         Catalyst Pharmaccuticals, Inc. <sup>(a)</sup> 59,577       1,001,489         Cerus Corp. <sup>(a)</sup> 129,404       279,513         CRISPR Therapeutics AG <sup>(a)(b)</sup> 14,614       914,836         Exact Sciences Corp. <sup>(b)</sup> 8,694       643,182         Ginkgo Bioworks Holdings, Inc. <sup>(a)(b)</sup> 516,449       872,799         Globus Medical, Inc., Class A <sup>(a)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128       796,643         Krystal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kyrata Biotech, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 3,030       928,786         Select Medical Holdings Corp.       22,226       522,311         Teladoe Health, Inc. <sup>(a)</sup> 3,030       928,786         Zynex, Inc. <sup>(a)(b)</sup> 23,488       646,647       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 23,488       646,155       2,752,323         Industrials — 3,92%       7,129       526,619         AAON, Inc.       7,129       526,619       21,52,982         Industrials — 3,92% <td>Beam Therapeutics, Inc.<sup>(a)</sup></td> <td>8,229</td> <td>223,993</td>	Beam Therapeutics, Inc. <sup>(a)</sup>	8,229	223,993
Catalyst Pharmaceuticals, Inc. <sup>(a)</sup> 59,577       1,001,489         Cerus Corp. <sup>(a)</sup> 129,404       279,513         CRISPR Therapeutics AG <sup>(a)</sup> ( <sup>(b)</sup> )       14,614       914,836         Exact Sciences Corp. <sup>(a)</sup> 8,694       643,182         Ginkgo Bioworks Holdings, Inc. <sup>(a)(b)</sup> 516,449       872,799         Globus Medical, Inc., Class A <sup>(a)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128       796,643         Krystal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kymera Therapeutics, Inc. <sup>(a)</sup> 3,030       928,786         Paeific Biosciences of California, Inc. <sup>(a)</sup> 3,030       928,786         Paeific Bioscience Corp. <sup>(b)</sup> 22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Tynex, Inc. <sup>(o)(b)</sup> 106,198       1,156,496         Vist Bioscience Corp. <sup>(b)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 3,112       23,488         AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,982         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682	Bridgebio Pharma, Inc. <sup>(a)</sup>	21,273	858,791
Cerus Corp. <sup>(a)</sup> 129,404       279,513         CRISPR Therapeutics AG <sup>(a)(b)</sup> 14,614       914,836         Exact Sciences Corp. <sup>(a)</sup> 8,694       643,182         Ginkgo Bioworks Holdings, Inc. <sup>(a)(b)</sup> 516,449       872,799         Globus Medical, Inc., Class A <sup>(a)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 26,128       796,663         Krystal Biotech, Inc. <sup>(a)</sup> 26,128       796,663         Krystal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kymera Therapeutics, Inc. <sup>(a)</sup> 23,889       608,214         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 3,030       28,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 145,574       1,428,081         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)(b)</sup> 106,198       _1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 126,984       779,682         Industrials — 3.92%       3,112       227,52,323         Industrials — 3.92%       5,446       305,085         ESAB Corp.       8,572       742,507	Castle Biosciences, Inc. <sup>(a)</sup>	16,554	357,235
CRISPR Therapeutics $AG^{(a)(b)}$ 14,614       914,836         Exact Sciences Corp. <sup>(a)</sup> 8,694       643,182         Ginkgo Bioworks Holdings, Inc. <sup>(a)(b)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128       796,643         Krystal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kymera Therapeutics, Inc. <sup>(a)</sup> 23,889       608,214         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 4,992       1,155,049         Medpace Holdings, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 30,300       928,786         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)</sup> 3,112       257,082         Achon, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682 <td>Catalyst Pharmaceuticals, Inc.<sup>(a)</sup></td> <td>59,577</td> <td>1,001,489</td>	Catalyst Pharmaceuticals, Inc. <sup>(a)</sup>	59,577	1,001,489
CRISPR Therapeutics $AG^{(a)(b)}$ 14,614       914,836         Exact Sciences Corp. <sup>(a)</sup> 8,694       643,182         Ginkgo Bioworks Holdings, Inc. <sup>(a)(b)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128       796,643         Krystal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kymera Therapeutics, Inc. <sup>(a)</sup> 23,889       608,214         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 4,992       1,155,049         Medpace Holdings, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 30,300       928,786         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)</sup> 3,112       257,082         Achon, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682 <td>Cerus Corp.<sup>(a)</sup></td> <td>129,404</td> <td>279,513</td>	Cerus Corp. <sup>(a)</sup>	129,404	279,513
Exact Sciences Corp. <sup>(a)</sup> 8,694       643,182         Ginkgo Bioworks Holdings, Inc. <sup>(a)(b)</sup> 516,449       872,799         Globus Medical, Inc., Class A <sup>(a)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128       796,643         Krystal Biotech, Inc. <sup>(a)</sup> 23,889       608,214         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 145,574       1,428,081         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zyr5,323       Industrials — 3.92%       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,693       274,160         Enovis Corp. <sup>(a)</sup> 5,446       305,085,852       25AB       209,930       274,160         Materials — 0.64%       2	•	14,614	
Globus Medical, Inc., Class A <sup>(a)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128       796,643         Krystal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kymera Therapeutics, Inc. <sup>(a)</sup> 23,889       608,214         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 4,992       1,155,049         Medpace Holdings, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 145,574       1,428,081         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 11,156,496       22,752,323         Industrials — 3.92%       22,752,323       11         AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602	-	8,694	
Globus Medical, Inc., Class A <sup>(a)</sup> 9,352       498,368         Guardant Health, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128       796,643         Krystal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kymera Therapeutics, Inc. <sup>(a)</sup> 23,889       608,214         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 4,992       1,155,049         Medpace Holdings, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 145,574       1,428,081         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 11,156,496       22,752,323         Industrials — 3.92%       22,752,323       11         AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602	*	516,449	
Guardant Health, Inc. <sup>(a)</sup> 35,219       952,674         Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128       796,643         Krystal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kymera Therapeutics, Inc. <sup>(a)</sup> 23,889       608,214         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 4,992       1,155,049         Medpace Holdings, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 145,574       1,428,081         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Wist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         22,752,323       Industrials — 3.92%       71,29       526,619         AcNor, Inc.       7,129       526,619       22,602         Allegiant Travel Co.       3,112       257,082       52,446       305,085         ESAB Corp.       8,572       742,507       742,507       79,682       79,930       274,160       3,017,737         Materials — 0.64%       21,321       493,368       3,017,737       3,017,737		9,352	
Intellia Therapeutics, Inc. <sup>(a)</sup> 26,128       796,643         Krystal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kymera Therapeutics, Inc. <sup>(a)</sup> 23,889       608,214         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 145,574       1,428,081         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         22,752,323       10       22,752,323         Industrials — 3.92%       12       257,082         AcON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 79,930       227,137         Materials — 0.64%       21,321       493,368         Real Estate — 0.98%		·	,
Krystal Biotech, Inc. <sup>(a)</sup> 5,726       710,368         Kymera Therapeutics, Inc. <sup>(a)</sup> 23,889       608,214         Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 4,992       1,155,049         Medpace Holdings, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 145,574       1,428,081         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 126,984       779,682         AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602         Wheels Up Experience,			
Kymera Therapeutics, Inc. (a)23,889608,214Madrigal Pharmaceuticals, Inc. (a)4,9921,155,049Medpace Holdings, Inc. (a)3,030928,786Pacific Biosciences of California, Inc. (a)145,5741,428,081Select Medical Holdings Corp.22,226522,311Teladoc Health, Inc. (a)63,5911,370,386Twist Bioscience Corp. (a)46,6471,719,409Veracyte, Inc. (a)23,488646,155Zynex, Inc. (a)(b)11,56,49622,752,323Industrials — 3.92%22,752,323106,198AAON, Inc.7,129526,619Allegiant Travel Co.3,112257,082Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984779,682Enovis Corp. (a)5,446305,085ESAB Corp.8,572742,507Forrester Research, Inc. (a)79,930274,160Wheels Up Experience, Inc. (a)79,930274,160Materials — 0.64%21,321493,368Real Estate — 0.98%21,321493,368Real Estate — 0.98%8,276208,721	•		,
Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> 4,992       1,155,049         Medpace Holdings, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 145,574       1,428,081         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 126,084       779,682         AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 79,930       274,160         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930       274,160         Materials — 0.64%       21,321       493,368         Real Estate — 0.98%	•		
Medpace Holdings, Inc. <sup>(a)</sup> 3,030       928,786         Pacific Biosciences of California, Inc. <sup>(a)</sup> 145,574       1,428,081         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 106,198       22,752,323         Industrials — 3.92%       7,129       526,619         AAON, Inc.       7,129       526,619         Alegiant Travel Co.       3,112       257,082         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930       274,160         Materials — 0.64%       21,321       493,368         Real Estate — 0.98%       21,321       493,368         Real Estate — 0.98%       34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721	· ·		
Pacific Biosciences of California, Inc. <sup>(a)</sup> 145,574       1,428,081         Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 1,156,496       22,752,323         Industrials — 3.92%       7,129       526,619         AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 49,466       132,602         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930       274,160         Materials — 0.64%       21,321       493,368         Real Estate — 0.98%       21,321       493,368         Real Estate — 0.98%       34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721			
Select Medical Holdings Corp.       22,226       522,311         Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zuz,752,323       100,198       1,156,496         Zuz,752,323       104strials — 3.92%       3,112       257,082         AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930       274,160         Wheels Up Experience, Inc. <sup>(a)</sup> 3,017,737         Materials — 0.64%       21,321       493,368         Element Solutions, Inc.       21,321       493,368         Real Estate — 0.98%       24,946       543,138         Legacy Housing Corp. <sup>(a)</sup> 34,996       543,1			
Teladoc Health, Inc. <sup>(a)</sup> 63,591       1,370,386         Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 1,156,496       22,752,323         Industrials — 3.92%       7,129       526,619         AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930       274,160         Wheels Up Experience, Inc. <sup>(a)</sup> 21,321       493,368         Real Estate — 0.98%       21,321       493,368         Real Estate — 0.98%       34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 34,996       543,138			
Twist Bioscience Corp. <sup>(a)</sup> 46,647       1,719,409         Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Z2,752,323       22,752,323         Industrials — 3.92%       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930       274,160         Materials — 0.64%       21,321       493,368         Real Estate — 0.98%       34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721	• •		
Veracyte, Inc. <sup>(a)</sup> 23,488       646,155         Zynex, Inc. <sup>(a)(b)</sup> 106,198       1,156,496         Zynex, Inc. <sup>(a)(b)</sup> 22,752,323         Industrials — 3.92%       7129       526,619         AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930       274,160         Materials — 0.64%       21,321       493,368         Real Estate — 0.98%       21,321       493,368         exp World Holdings, Inc. <sup>(b)</sup> 34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721		·	
Zynex, Inc. (a)(b) $106,198$ $1,156,496$ $22,752,323$ Industrials — 3.92%7129526,619AAON, Inc.7,129526,619Allegiant Travel Co.3,112257,082Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984779,682Enovis Corp. <sup>(a)</sup> 5,446305,085ESAB Corp.8,572742,507Forrester Research, Inc. <sup>(a)</sup> 4,946132,602Wheels Up Experience, Inc. <sup>(a)</sup> 79,930274,160Materials — 0.64%21,321493,368Element Solutions, Inc.21,321493,368Real Estate — 0.98%34,996543,138Legacy Housing Corp. <sup>(a)</sup> 8,276208,721	·	·	
Industrials — 3.92% $22,752,323$ AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class A <sup>(a)(b)</sup> 126,984       779,682         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930       274,160         Materials — 0.64%       21,321       493,368         Element Solutions, Inc.       21,321       493,368         Real Estate — 0.98%       34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721	· · · · · · · · · · · · · · · · · · ·		
Industrials — 3.92%       7,129       526,619         AAON, Inc.       7,129       526,619         Allegiant Travel Co.       3,112       257,082         Archer Aviation, Inc., Class $A^{(a)(b)}$ 126,984       779,682         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930       274,160         Materials — 0.64%       3,017,737         Element Solutions, Inc.       21,321       493,368         Real Estate — 0.98%       34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721			
Allegiant Travel Co. $3,112$ $257,082$ Archer Aviation, Inc., Class A <sup>(a)(b)</sup> $126,984$ $779,682$ Enovis Corp. <sup>(a)</sup> $5,446$ $305,085$ ESAB Corp. $8,572$ $742,507$ Forrester Research, Inc. <sup>(a)</sup> $4,946$ $132,602$ Wheels Up Experience, Inc. <sup>(a)</sup> $79,930$ $274,160$ Materials — 0.64% $21,321$ $493,368$ Real Estate — 0.98% $21,321$ $493,368$ Legacy Housing Corp. <sup>(a)</sup> $34,996$ $543,138$	Industrials — 3.92%		
Archer Aviation, Inc., Class $A^{(a)(b)}$ 126,984       779,682         Enovis Corp. <sup>(a)</sup> 5,446       305,085         ESAB Corp.       8,572       742,507         Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930       274,160         Materials — 0.64%       3,017,737         Element Solutions, Inc.       21,321       493,368         Real Estate — 0.98%       24,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721	AAON, Inc.	7,129	526,619
Enovis Corp. <sup>(a)</sup> 5,446 $305,085$ ESAB Corp. $8,572$ $742,507$ Forrester Research, Inc. <sup>(a)</sup> $4,946$ $132,602$ Wheels Up Experience, Inc. <sup>(a)</sup> $79,930$ $274,160$ Materials — 0.64% $21,321$ $493,368$ Element Solutions, Inc. $21,321$ $493,368$ Real Estate — 0.98% $34,996$ $543,138$ Legacy Housing Corp. <sup>(a)</sup> $8,276$ $208,721$	Allegiant Travel Co.	3,112	257,082
ESAB Corp. $8,572$ $742,507$ Forrester Research, Inc. <sup>(a)</sup> $4,946$ $132,602$ Wheels Up Experience, Inc. <sup>(a)</sup> $79,930$ $274,160$ Materials — 0.64% $21,321$ $493,368$ Element Solutions, Inc. $21,321$ $493,368$ Real Estate — 0.98% $34,996$ $543,138$ Legacy Housing Corp. <sup>(a)</sup> $8,276$ $208,721$	Archer Aviation, Inc., Class A <sup>(a)(b)</sup>	126,984	779,682
Forrester Research, Inc. <sup>(a)</sup> 4,946       132,602         Wheels Up Experience, Inc. <sup>(a)</sup> 79,930 $274,160$ Materials — 0.64%       3,017,737         Element Solutions, Inc.       21,321       493,368         Real Estate — 0.98%       34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721	Enovis Corp. <sup>(a)</sup>	5,446	305,085
Wheels Up Experience, Inc. <sup>(a)</sup> 79,930 $274,160$ Materials — 0.64%       3,017,737         Element Solutions, Inc.       21,321       493,368         Real Estate — 0.98%       493,368         eXp World Holdings, Inc. <sup>(b)</sup> 34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721	ESAB Corp.	8,572	742,507
Materials — 0.64%       3,017,737         Element Solutions, Inc.       21,321         493,368       493,368         Real Estate — 0.98%       34,996         eXp World Holdings, Inc. <sup>(b)</sup> 34,996         Legacy Housing Corp. <sup>(a)</sup> 8,276	Forrester Research, Inc. <sup>(a)</sup>	4,946	132,602
Materials — 0.64%	Wheels Up Experience, Inc. <sup>(a)</sup>	79,930	274,160
Element Solutions, Inc.       21,321       493,368         Real Estate — 0.98%          eXp World Holdings, Inc. <sup>(b)</sup> 34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721			3,017,737
Real Estate — 0.98%         eXp World Holdings, Inc. <sup>(b)</sup> Legacy Housing Corp. <sup>(a)</sup> 8,276         208,721	Materials — 0.64%		
eXp World Holdings, Inc. <sup>(b)</sup> 34,996       543,138         Legacy Housing Corp. <sup>(a)</sup> 8,276       208,721	Element Solutions, Inc.	21,321	493,368
Legacy Housing Corp. <sup>(a)</sup> 8,276         208,721	Real Estate — 0.98%		
	eXp World Holdings, Inc. <sup>(b)</sup>	34,996	543,138
751,859	Legacy Housing Corp. <sup>(a)</sup>	8,276	208,721
			751,859

# SCHEDULE OF INVESTMENTS (Continued)

December 31, 2023 (Unaudited)

	Shares	Fair Value
Common Stocks (continued)		
Technology — 37.51%		
Affirm Holdings, Inc. <sup>(a)(b)</sup>	46,969	\$ 2,308,056
Altair Engineering, Inc., Class A <sup>(a)</sup>	14,060	1,183,149
Appian Corp. <sup>(a)</sup>	21,402	805,999
Asana, Inc., Class A <sup>(a)</sup>	55,065	1,046,786
Bill.com Holdings, Inc. <sup>(a)</sup>	25,325	2,066,268
Coherent Corp. <sup>(a)</sup>	14,260	620,738
Fastly, Inc., Class A <sup>(a)</sup>	53,722	956,252
Impinj, Inc. <sup>(a)</sup>	5,522	497,146
Lattice Semiconductor Corp. <sup>(a)</sup>	11,755	810,977
MaxLinear, Inc. <sup>(a)</sup>	45,068	1,071,266
Moneylion, Inc. <sup>(a)</sup>	7,413	464,721
Omnicell, Inc. <sup>(a)</sup>	15,867	597,075
PagerDuty, Inc. <sup>(a)</sup>	63,602	1,472,387
Pegasystems, Inc.	28,329	1,384,155
Phreesia, Inc. <sup>(a)</sup>	21,666	501,568
PubMatic, Inc., Class A <sup>(a)</sup>	62,830	1,024,757
Sanmina Corp. <sup>(a)</sup>	13,920	715,070
Schrodinger, Inc. <sup>(a)</sup>	23,832	853,186
Simulations Plus, Inc.	6,983	312,489
Sprout Social, Inc., Class A <sup>(a)</sup>	9,235	567,398
Super Micro Computer, Inc. <sup>(a)</sup>	3,434	976,149
Toast, Inc., Class A <sup>(a)</sup>	120,029	2,191,730
TTEC Holdings, Inc.	37,313	808,573
UiPath, Inc., Class A <sup>(a)</sup>	43,091	1,070,380
Upstart Holdings, Inc. <sup>(a)(b)</sup>	48,632	1,987,104
Vicor Corp. <sup>(a)</sup>	10,379	466,432
Wolfspeed, Inc. <sup>(a)</sup>	23,420	1,019,004
Zuora, Inc. <sup>(a)</sup>	119,157	1,120,076
		28,898,891
Total Common Stocks (Cost \$64,739,640)		76,105,100

### SCHEDULE OF INVESTMENTS (Continued)

December 31, 2023 (Unaudited)

	Shares	Fair Value
Money Market Funds — 12.29% Fidelity Investments Money Market Treasury Only Portfolio, Class I, 5.24% <sup>(c)</sup> Invesco Government & Agency Portfolio, Class I, 5.28% <sup>(c)(d)</sup>	856,621 8,613,434	\$ 856,621 8,613,434
Total Money Market Funds (Cost \$9,470,055)		9,470,055
Total Investments — 111.10% (Cost \$74,209,695) Liabilities in Excess of Other Assets — (11.10)% Net Assets — 100.00%		\$ 85,575,155 (8,548,083) <u>\$ 77,027,072</u>

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> All or a portion of the security is on loan as of December 31, 2023. The total value of the securities on loan as of December 31, 2023 was \$7,970,321.

<sup>(c)</sup> Rate disclosed is the seven day effective yield as of December 31, 2023.

<sup>(d)</sup> All or a portion of this security was purchased with cash proceeds from securities lending. Total collateral had a value of \$8,613,434. See Note 2.

ADR - American Depositary Receipt

### STATEMENTS OF ASSETS AND LIABILITIES

December 31, 2023 (Unaudited)

	ERShares Global Entrepreneurs	ERShares US Small Cap
Assets		
Investments, at cost	\$ 50,725,779	<u>\$ 74,209,695</u>
Investments at fair value <sup>(a)</sup>	55,232,754	85,575,155
Cash	10,597	
Receivable for fund shares sold		99,950
Dividends and interest receivable	42,291	7,615
Securities lending income receivable	569	9,298
Tax reclaims receivable	33,387	1,223
Prepaid expenses	5,829	13,128
Total Assets	55,325,427	85,706,369
Liabilities		
Collateral due to broker for securities loaned	2,098,487	8,613,434
Due to custodian	1,848	1,920
Payable to Advisor	31,381	40,531
Payable to Administrator	2,231	_
Payable to Trustees	2,838	5,334
Accrued expenses and other liabilities	17,044	18,078
Total Liabilities	2,153,829	8,679,297
Net Assets	\$ 53,171,598	\$ 77,027,072
Net Assets consist of:		
Paid-in capital	77,710,666	86,290,953
Accumulated deficit	(24,539,068)	(9,263,881)
Net Assets	\$ 53,171,598	\$ 77,027,072
Institutional Class	<u> </u>	<u> </u>
Net Assets	\$ 53,171,598	\$ 77,027,072
Shares outstanding (unlimited number of shares authorized, \$0.01 par value)	4,357,437	11,403,043
Net asset value and offering price per share	<u>\$ 12.20</u>	\$ 6.75
Redemption price per share (NAV * 98%) <sup>(b)</sup>	\$ 11.96	\$ 6.62

<sup>(a)</sup> Includes securities on loan of \$1,973,043 and 7,970,321, respectively. See Note 2.

<sup>(b)</sup> The Fund charges a 2.00% redemption fee on shares redeemed within five business days of purchase. Shares are redeemed at the NAV if held longer than five business days. See Note 8.

### **STATEMENTS OF OPERATIONS**

For the six months ended December 31, 2023 (Unaudited)

		ERShares Global htrepreneurs		ERShares US Small Cap
Investment Income				
Dividend income (net of foreign taxes withheld of \$7,642 and \$66)	\$	196,631	\$	121,238
Interest income		52,553		98,070
Securities lending income		1,107		19,828
Total investment income		250,291		239,136
Expenses				
Advisory fees		219,604		280,831
Fund accounting and administration fees		17,977		22,811
Auditing fees		7,368		7,368
Custodian fees		5,965		2,885
Transfer agent		5,236		5,522
Registration fees		5,049		10,444
Legal fees		4,994		8,119
Trustees' fees and expenses		4,983		7,718
Shareholder reporting fees		2,960		4,649
Insurance expense		1,712		3,918
Pricing fees		1,146		2,005
Miscellaneous		5,307		3,837
Total expenses		282,301		360,107
Fees contractually waived by Advisor		(40,325)		(40,917)
Net operating expenses		241,976		319,190
Net investment income (loss)		8,315		(80,054)
<b>Net Realized and Change in Unrealized Gain (Loss)</b> Net realized gain (loss) on:				
Investments		827,090		(1,146,802)
Foreign currency transactions		(2,158)		(1,140,002)
Net realized gain (loss)		824,932		(1,146,802)
Change in unrealized appreciation on: Investments Foreign currency translations Net change in unrealized appreciation		2,324,285 1,464 2,325,749		4,007,439
Net realized and change in unrealized appreciation on investments	<u>_</u>	3,150,681	<u>م</u>	2,860,637
Net increase in net assets resulting from operations	<u>\$</u>	3,158,996	\$	2,780,583

### STATEMENTS OF CHANGES IN NET ASSETS

	<b>ERShares Global Entrepreneurs</b>			ER	ERShares US Small Cap			
	For t Six Mo Endo Decemb 202	nths ed er 31,	Ye	For the ar Ended e 30, 2023	Six N Ei Decen	r the Aonths Ided Iber 31, 023		For the Year Ended Ine 30, 2023
	(Unaud	ited)			(Una	udited)		
Increase (Decrease) in Net Assets from:								
Operations:								
Net investment income (loss)	\$	8,315	\$	73,261	\$	(80,054)	\$	(165,559)
Net realized gain (loss) on investments and								
foreign currency transactions	82	4,932	(	(3,898,612)	(1,	146,802)		(436,013)
Net change in unrealized appreciation on								
investments and foreign currency translations	2,32	5,749		9,467,890	4,	007,439		15,590,805
Net increase in net assets resulting from		0.007						1 4 0 0 0 0 0 0
operations	3,15	8,996		5,642,539	2,	780,583		14,989,233
Distributions to Shareholders from Earnings:	()	7 4 4 7 )						
Institutional Class Total distributions to shareholders		7,447)						
total distributions to snareholders	(3	7,447)						
Capital Transactions:								
Institutional Class								
Proceeds from shares sold		3,854		11,274		591,057		144,058
Reinvestment of distributions		7,346				091,007		11,050
Cost of shares redeemed		7,298)		(796,100)	(20)	423,869)		(957,609)
Net increase (decrease) in net assets resulting	(1	<u>,,_,</u> )		(190,100)		(120,00)		(501,005)
from capital transactions	2	3,902		(784,826)	(19.	832,812)		(813,551)
Total Increase in Net Assets		5,451		4,857,713		052,229)		14,175,682
	- )	- ) -		))	( )	, - ,		, ,
Net Assets								
Beginning of period	50,02	6,147	4	45,168,434	94,	079,301		79,903,619
End of period	\$ 53,17	1,598	<u>\$</u> 5	50,026,147	<u></u> \$77,	027,072	\$	94,079,301
Share Transactions								
Shares sold		343		1,052		87,350		24,923
Shares issued in reinvestment of distributions		3,118						
Shares redeemed		1,544)		(77,658)		183,526)		(159,925)
Net increase (decrease) in shares outstanding		1,917		(76,606)	(3,	096,176)		(135,002)

### FINANCIAL HIGHLIGHTS – Institutional Class

(For a share outstanding during each period)

	For the Six Months Ended December 31, 2023 (Unaudited)	For the Year Ended June 30, 2023	For the Year Ended June 30, 2022	For the Year Ended June 30, 2021	For the Year Ended June 30, 2020	For the Year Ended June 30, 2019
Selected Per Share Data:	· · · ·					
Net asset value, beginning of period	\$11.49	\$10.19	\$21.82	\$16.82	\$15.78	\$16.07
Investment operations:						
Net investment income (loss) <sup>(a)</sup>	(b)	0.02	(0.10)	(0.14)	(0.08)	(0.06)
Net realized and unrealized gain (loss)	0.72	1.28	(7.22)	7.32	1.61	0.16
Total from investment operations	0.72	1.30	(7.32)	7.18	1.53	0.10
Less distributions to shareholders from:						
Net investment income	(0.01)		(0.15)			
Net realized gains			(4.16)	(2.18)	(0.49)	(0.39)
Total distributions	(0.01)		(4.31)	(2.18)	(0.49)	(0.39)
Paid in capital from redemption fees		_	_	(b)	(b)	(b)
Net asset value, end of period	\$12.20	\$11.49	\$10.19	\$21.82	\$16.82	\$15.78
Total Return <sup>(c)</sup>	6.26% <sup>(d)</sup>	12.76%	(39.05)%	42.63%	9.80%	1.11%
Ratios and Supplemental Data:						
Net assets, end of period (000 omitted)	\$53,172	\$50,026	\$45,168	\$121,627	\$51,234	\$63,784
Ratio of expenses to average net assets:						
Before fees waived	1.14% <sup>(e)</sup>	1.17%	1.37%	1.44%	1.49%	1.47%
After fees waived	0.98% <sup>(e)</sup>	0.98%	1.29%	1.44%	1.49%	1.56%
Ratio of net investment income (loss) to average net assets:						
Before fees waived	(0.13)%	(0.03)%	(0.70)%	(0.67)%	(0.51)%	(0.27)%
After fees waived	0.03% <sup>(e)</sup>	0.16%	(0.63)%	(0.67)%	(0.51)%	(0.36)%
Portfolio turnover rate	105% <sup>(d)</sup>	94%	265%	477% <sup>(f)</sup>	61%	23%

<sup>(a)</sup> Based on average shares outstanding during the period.

<sup>(b)</sup> Rounds to less than \$0.005 per share.

(c) Total returns would have been lower/higher had certain expenses not been waived/recovered by the Advisor (see Note 3). Returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemptions of Fund shares.

<sup>(d)</sup> Not annualized.

(e) Annualized.

<sup>(f)</sup> The Fund has experienced an unusual interest rate environment combined with volatile markets resulting from inflationary concerns. These two factors posed potential adverse effects to the Fund. Thus, the portfolio manager engaged in temporary defensive positions as well as positioned the Fund to take the best advantage of the environment it was facing. These two actions, combined with a reversion of the defensive positions, resulted in an increased turnover for the Fund.

### FINANCIAL HIGHLIGHTS – Institutional Class

(For a share outstanding during each period)

	For the Six Months Ended December 31, 2023 (Unaudited)	For the Year Ended June 30, 2023	For the Year Ended June 30, 2022	For the Year Ended June 30, 2021	For the Year Ended June 30, 2020	For the Year Ended June 30, 2019
Selected Per Share Data:						
Net asset value, beginning of period	\$ 6.49	\$ 5.46	\$15.03	\$12.01	\$12.71	\$15.27
Investment operations:						
Net investment income (loss) <sup>(a)</sup>	(0.01)	(0.01)	0.02	(0.06)	(0.01)	(b)
Net realized and unrealized gain (loss)	0.27	1.04	(3.66)	5.35	0.11	(0.28)
Total from investment operations	0.26	1.03	(3.64)	5.29	0.10	(0.28)
Less distributions to shareholders from:						
Net investment income			(0.16)		(0.01)	
Net realized gains			(5.77)	(2.27)	(0.79)	(2.28)
Total distributions			(5.93)	(2.27)	(0.80)	(2.28)
Paid in capital from redemption fees				(b)	(b)	(b)
Net asset value, end of period	\$ 6.75	\$ 6.49	\$ 5.46	\$15.03	\$12.01	\$12.71
Total Return <sup>(c)</sup>	4.01% <sup>(d)</sup>	18.86%	(35.35)%	42.19%	0.86%	1.58%
<b>Ratios and Supplemental Data:</b>						
Net assets, end of period (000 omitted)	\$77,027	\$94,079	\$79,904	\$153,628	\$163,828	\$160,710
Ratio of expenses to average net assets:						
Before fees waived	0.96% <sup>(e)</sup>	0.95%	0.88%	0.87%	0.90%	0.89%
After fees waived	0.85% <sup>(e)</sup>	0.85%	0.85%	0.85%	0.85%	0.85%
Ratio of net investment income (loss) to average net assets:						
Before fees waived	(0.21)%	(0.29)%	0.13%	(0.43)%	(0.10)%	(0.05)%
After fees waived	$(0.15)\%^{(e)}$	(0.19)%	0.16%	(0.41)%	(0.05)%	(0.01)%
Portfolio turnover rate	86% <sup>(d)</sup>	63%	175%	439% <sup>(f)</sup>	139% <sup>(f)(g)</sup>	43%

<sup>(a)</sup> Based on average shares outstanding during the period.

<sup>(b)</sup> Rounds to less than \$0.005 per share.

(c) Total returns would have been lower/higher had certain expenses not been waived/recovered by the Advisor (see Note 3). Returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemptions of Fund shares.

<sup>(d)</sup> Not annualized.

(e) Annualized.

### FINANCIAL HIGHLIGHTS (Continued)

- <sup>(f)</sup> The Fund has experienced an unusual interest rate environment combined with volatile markets resulting from inflationary concerns. These two factors posed potential adverse effects to the Fund. Thus, the portfolio manager engaged in temporary defensive positions as well as positioned the Fund to take the best advantage of the environment it was facing. These two actions, combined with a reversion of the defensive positions, resulted in an increased turnover for the Fund.
- <sup>(g)</sup> Given the abnormal market circumstances during the quarter ending June 30, 2020, as a result of the COVID-19 situation; the Fund had taken a temporary defensive approach. Implementing the temporary defensive measure resulted in the increase in portfolio turnover for the Fund.

#### **NOTES TO FINANCIAL STATEMENTS December 31, 2023 (Unaudited)**

#### 1. ORGANIZATION

EntrepreneurShares<sup>TM</sup> Series Trust, a Delaware statutory trust (the "Trust"), was formed on July 1, 2010, and has authorized capital of unlimited shares of beneficial interest. The Trust is an open-end management investment company registered under the Investment Company Act of 1940, as amended (the "1940 Act"), and is authorized to issue multiple series and classes of shares. ERShares Global Entrepreneurs (the "Global Fund", formerly known as EntrepreneurShares Global Fund) and ERShares US Small Cap (the "US Small Cap Fund", formerly known as Entrepreneur US Small Cap Fund (each separately a "Fund", or collectively, "the Funds") are each classified as a "diversified" series, as defined in the 1940 Act. The Funds are investment companies and, accordingly, follow the investment company accounting and reporting guidance of the Financial Accounting Standards Board Accounting Standards Codification Topic 946 – Investment Companies including Accounting Standards Update ("ASU") 2013-08. The Global Fund commenced operations on November 11, 2010. The US Small Cap Fund commenced operations on December 17, 2013.

The investment objective of the Global Fund is long-term capital appreciation. The Global Fund seeks to achieve its objective by investing mainly in equity securities of global companies with market capitalizations that are above \$300 million at the time of initial purchase and possess entrepreneurial characteristics, as determined by EntrepreneurShares, LLC, (the "Sub Advisor"), the Global Fund's Sub-Advisor, and Seaport Global Advisors, LLC formerly known as Weston Capital Advisors, LLC, the Global Fund's investment advisor (the "Global Advisors"). Dr. Joel M. Shulman has been the Global Fund's portfolio manager since November 11, 2010 and Managing Director of the Advisor and President of the Sub-Advisor.

The investment objective of the US Small Cap Fund is long-term capital appreciation. The US Small Cap Fund seeks to achieve its objective by investing at least 80% of its net assets (plus any borrowing for investment purposes) in equity securities of U.S. companies with market capitalization that are below that of the largest member of the Russell 2000 Index at the time of initial purchase and possess entrepreneurial characteristics, as determined by Capital Impact Advisors, LLC (the "Advisor", collectively with the Global Advisor, the "Advisors"), the US Small Cap Fund's investment advisor. Dr. Joel M. Shulman has been the US Small Cap Fund's portfolio manager since December 17, 2013 and Chief Executive Officer of the Advisor.

The Global Fund has registered three classes of shares: Class A shares, Retail Class shares and Institutional Class shares. The US Small Cap Fund has registered two classes of shares: Institutional Class shares and Retail Class shares. Each share represents an equal proportionate interest in the assets and liabilities belonging to the applicable class and is entitled to such dividends and distributions out of income belonging to the applicable class as are declared by the EntrepreneurShares Series Trust Board of Trustees (the "Board"). On matters that affect the Fund as a whole, each class has the same voting and other rights and preferences as any other class. On matters that affect only one class, only shareholders of that class may vote. Each class votes separately on matters affecting only that class, or on matters expressly required to be voted on separately by state or federal law. Shares of each class of a series have the same voting and other rights and preferences as the other classes and series of the Trust for matters that affect the Trust as a whole. Currently, only Institutional Class shares of each of the Global Fund and US Small Cap Fund are being offered.

### NOTES TO FINANCIAL STATEMENTS (Continued) December 31, 2023 (Unaudited)

#### 2. SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies consistently followed by the Funds in the preparation of their financial statements. These policies are in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP").

#### **Regulatory Update**

*Tailored Shareholder Reports for Mutual Funds and Exchange-Traded Funds ("ETFs")* – Effective January 24, 2023, the Securities and Exchange Commission (the "SEC") adopted rule and form amendments to require mutual funds and ETFs to transmit concise and visually engaging streamlined annual and semiannual reports to shareholders that highlight key information. Other information, including financial statements, will no longer appear in a streamlined shareholder report but must be available online, delivered free of charge upon request, and filed on a semiannual basis on Form N-CSR. The rule and form amendments have a compliance date of July 24, 2024. At this time, management is evaluating the impact of these amendments on the shareholder reports for the Funds.

#### **Investment Valuation**

The following is a summary of the Funds' pricing procedures. It is intended to be a general discussion and may not necessarily reflect all pricing procedures followed by the Funds.

In determining the net asset value ("NAV") of the Funds' shares, securities that are listed on a national securities exchange (other than the National Association of Securities Dealers' Automatic Quotation System ("Nasdaq")) are valued at the last sale price on the day the valuation is made. Securities that are traded on Nasdaq under one of its three listing tiers, Nasdaq Global Select Market, Nasdaq Global Market and Nasdaq Capital Market, are valued at the Nasdaq Official Closing Price. Price information on listed securities is taken from the exchange where the security is primarily traded. Securities which are listed on an exchange but which are not traded on the valuation date are valued at the most recent bid price.

Unlisted securities held by the Funds are valued at the average of the quoted bid and ask prices in the over-the-counter market. Securities and other assets for which market quotations are not readily available are valued at their fair value as determined in good faith under procedures established by and under the general supervision and responsibility of the EntrepreneurShares Series Trust Board of Trustees (the "Board"). Investments in registered open-end investment companies other than exchange-traded funds are valued at the reported NAV.

Short-term investments with 61 days or more to maturity at time of purchase are valued at fair market value through the 61st day prior to maturity, based on quotations received from market makers or other appropriate sources; thereafter, they are generally valued at amortized cost. There is no definitive set of circumstances under which the Funds may elect to use fair value procedures to value a security. Types of securities that the Funds may hold for which fair value pricing might be required include, but are not limited to: (a) illiquid securities, including restricted securities and private placements for which there is no public market; (b) options not traded on a securities exchange; (c) securities of an issuer that has entered into a restructuring; (d) securities whose trading has been halted or suspended, as permitted by the SEC; (e) foreign securities, if an event or development has occurred subsequent to the close of the foreign market and prior to the close of regular trading on the New York Stock Exchange that would materially affect the value of the security; and (f) fixed income securities that have gone into default and for which there is not a current market value quotation.

Valuing securities at fair value involves greater reliance on judgment than securities that have readily available market quotations. There can be no assurance that the Funds could obtain the fair value price assigned to a security upon sale.

### **NOTES TO FINANCIAL STATEMENTS (Continued)** December 31, 2023 (Unaudited)

Securities that are not listed on an exchange are valued by the Funds' Advisors, under the supervision of the Board. There is no single standard for determining the fair value of a security. Rather, in determining the fair value of a security, the Advisors and the Board take into account the relevant factors and surrounding circumstances, which may include: (1) the nature and pricing history (if any) of the security; (2) whether any dealer quotations for the security are available; (3) possible valuation methodologies that could be used to determine the fair value of the security; (4) the recommendation of the portfolio manager of the Funds with respect to the valuation of the security; (5) whether the same or similar securities are held by other funds managed by the Advisors or other funds and the method used to price the security in those funds; (6) the extent to which the fair value to be determined for the security will result from the use of data or formulae produced by third parties independent of the Advisors; and (7) the liquidity or illiquidity of the market for the security.

#### Fair Value Measurement

The Funds have adopted authoritative fair valuation accounting standards which establish an authoritative definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value, a discussion of changes in valuation techniques and related inputs during the year and expanded disclosure of valuation levels for major security types. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

- Level 1: Unadjusted quoted prices in active markets for identical assets that the Funds have the ability to access at the measurement date;
- Level 2: Observable inputs other than quoted prices included in Level 1 that are observable for the asset either directly or indirectly. These inputs may include quoted prices for identical instruments on inactive markets, quoted prices for similar instruments, interest rates, prepayment spreads, credit risk, yield curves, default rates, and similar data;
- Level 3: Significant unobservable inputs for the asset to the extent that relevant observable inputs are not available, representing the Funds' own assumptions that a market participant would use in valuing the asset, and would be based on the best information available.

Inputs are used in applying the various valuation techniques and broadly refer to the assumptions that market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, specific and broad credit data, liquidity statistics, and other factors. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. However, the determination of what constitutes "observable" requires significant judgment by the Funds. The Funds consider observable data to be that market data, which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to the Funds' perceived risk of that instrument.

Investments whose values are based on quoted market prices in active markets, and are therefore classified within Level 1, include active listed equities and real estate investment trusts, and certain money market securities. Investments that trade in markets that are not considered to be active, but are valued based on quoted market prices, dealer quotations or alternative pricing sources supported by observable inputs are classified within Level 2. Investments classified within Level 3 have significant unobservable inputs, as they trade infrequently or not at all. During the six months

### NOTES TO FINANCIAL STATEMENTS (Continued) December 31, 2023 (Unaudited)

ended December 31, 2023, the Funds did not hold any instrument which used significant unobservable inputs (Level 3) in determining fair value. The tables below are a summary of the inputs used to value the Funds' investments as of December 31, 2023.

Valuation Inputs					
Assets	Level 1	Level 2	Level 3	Total	
Global Fund*					
Common Stocks	\$ 51,917,200	\$	\$	\$ 51,917,200	
Money Market Funds	3,315,554			3,315,554	
Total	\$ 55,232,754	<u>\$                                    </u>	<u>\$                                    </u>	\$ 55,232,754	
US Small Cap Fund*					
Common Stocks	\$ 76,105,100	\$	\$	\$ 76,105,100	
Money Market Funds	9,470,055			9,470,055	
Total	<u>\$ 85,575,155</u>	<u>\$                                    </u>	<u>\$                                    </u>	\$ 85,575,155	

\* For further information regarding security characteristic, please see the Schedules of Investments.

The Funds did not hold any investments at the end of the reporting period in which significant unobservable inputs (Level 3) were used in determining fair value; therefore, no reconciliation of Level 3 securities is included for this reporting period.

#### **Use of Estimates and Indemnifications**

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in these financial statements. Actual results could differ from those estimates.

In the normal course of business, the Trust, on behalf of the Funds, enters into contracts that contain a variety of representations which provide general indemnifications. The Trust's maximum exposure under these arrangements is unknown; however, the Trust has not had claims or losses pursuant to these contracts and the Trust expects any risk of loss to be remote.

#### Federal Income Taxes

The Funds intend to continue to qualify as "regulated investment companies" under Sub-chapter M of the Internal Revenue Code of 1986, as amended. If so qualified, the Funds will not be subject to federal income tax to the extent they distribute substantially all of their net investment income and net realized gains to shareholders.

The Funds have reviewed all open tax years and major jurisdictions and concluded that the Funds did not have any tax positions that did not meet the "more-likely-than-not" threshold of being sustained by the applicable tax authority for the six months ended December 31, 2023. The Funds would recognize interest and penalties, if any, related to uncertain tax benefits in the Statements of Operations. During the six months ended December 31, 2023, the Funds did not incur any interest or penalties. Tax returns filed within the prior three years remain subject to examination by federal and state tax authorities.

### NOTES TO FINANCIAL STATEMENTS (Continued) December 31, 2023 (Unaudited)

#### **Distribution to Shareholders**

The Funds intend to continue to distribute to their shareholders any net investment income and any net realized long or short-term capital gains, if any, at least annually. Distributions are recorded on the ex-dividend date. The Funds may periodically make reclassifications among certain of their capital accounts as a result of the characterization of certain income and realized gains determined annually in accordance with federal tax regulations that may differ from U.S. GAAP.

#### Allocation of Expenses

Expenses incurred by the Trust that do not relate to a specific fund of the Trust are allocated to the individual funds by or under the direction of the Board in such a manner as the Board determine to be fair and equitable.

#### **Foreign Currency Transactions**

The Funds' books and records are maintained in U.S. dollars. Foreign currency denominated transactions (i.e., fair value of investment securities, assets and liabilities, purchases and sales of investment securities and income and expenses) are translated into U.S. dollars at the current rate of exchange on the date of valuation. Purchases and sales of securities and income items denominated in foreign currencies are translated into U.S. dollars at the exchange rate in effect on the transaction date. The Funds do not separately report the effect of changes in foreign exchange rates from changes in market prices on securities held. Such fluctuations are included in net realized and unrealized gain or (loss) on investments in the Statements of Operations.

Realized foreign exchange gains or losses arise from sales of foreign currencies, currency gains (losses) realized between the trade and settlement dates on securities transactions and the difference between the recorded amounts of dividends, interest and foreign taxes withheld, and the U.S. dollar equivalent of the amounts actually received or paid. Net unrealized foreign exchange gains (losses) arise from the changes in foreign exchange rates on foreign denominated assets and liabilities other than investments in securities held at the end of the reporting period.

#### **Investment Transactions and Investment Income**

Throughout the reporting period, security transactions are accounted for no later than one business day following the trade date. For financial reporting purposes, security transactions are accounted for on trade date on the last business day of the reporting period. The specific identification method is used for determining gains or losses for financial statements and income tax purposes. Dividend income, less any foreign tax withheld, is recognized on the ex-dividend date and interest income is recognized on an accrual basis, including amortization/accretion of premiums or discounts.

#### **Securities Lending**

Each Fund may lend portfolio securities constituting up to 33-1/3% of its total assets (as permitted by the 1940 Act) to unaffiliated broker-dealers, banks or other recognized institutional borrowers of securities, provided that the borrower at all times maintains cash, U.S. government securities or equivalent collateral or provides an irrevocable letter of credit in favor of the Fund equal in value to at least 102% of the value of loaned domestic securities and 105% of the value of loaned foreign securities on a daily basis. During the time portfolio securities are on loan, the borrower pays the lending Fund an amount equivalent to any dividends or interest paid on such securities, and such Fund may receive an agreed-upon amount of interest income from the borrower who delivered equivalent collateral or provided a letter of credit. Loans are subject to termination at the option of a Fund or the borrower. A Fund may pay reasonable administrative and custodial fees in connection with a loan of portfolio securities and may pay a negotiated portion of the interest earned on the cash or equivalent collateral to the borrower or placing broker. A Fund does not have the right to vote securities on loan but could terminate the loan and regain the right to vote if that were considered important with respect to the investment.

### NOTES TO FINANCIAL STATEMENTS (Continued) December 31, 2023 (Unaudited)

The primary risk in securities lending is a default by the borrower during a sharp rise in price of the borrowed security resulting in a deficiency in the collateral posted by the borrower. The Funds will seek to minimize this risk by requiring that the value of the securities loaned be computed each day and additional collateral be furnished each day if required.

#### **Disclosures about Offsetting Assets and Liabilities**

The Funds are required to disclose information about offsetting and related arrangements to enable users of its financial statements to understand the effect of those arrangements on its financial position. The guidance requires retrospective application for all comparative periods presented. Management has evaluated the impact on the financial statement disclosures and determined that there is no effect. As there are no master netting arrangements relating to the Funds' participation in securities lending, and all amounts related to securities lending are presented gross on the Funds' Statement of Assets and Liabilities, no additional disclosures have been made on behalf of the Funds. Please refer to the Securities Lending Note for additional disclosures related to securities lending, including collateral related to securities on loan.

#### **3. AGREEMENTS**

#### **Global Fund's Investment Advisory Agreement**

Seaport Global Advisors, LLC, a related party of the Global Fund, oversees the performance of the Global Fund and is responsible for overseeing the management of the investment portfolio of the Global Fund. These services are provided under the terms of an investment advisory agreement between the Trust and Global Advisors, pursuant to which Global Advisors receives an annual advisory fee equal to 0.89%. Through November 1, 2024, the Advisor has agreed to waive and/or reimburse the Global Fund for its advisory fee, and to the extent necessary, bear other expenses, to limit the total annualized expenses (excluding borrowing and investment-related costs and fees, taxes, extraordinary expenses and fees and expenses of underlying funds) of the Institutional Class shares of the Global Fund to the amounts of 0.98% per annum of net assets attributable to such shares of the Global Fund.

Global Advisors shall be permitted to recover expenses it has borne subsequent to the effective date of this agreement (whether through reduction of its advisory fee or otherwise) in later periods to the extent that the Global Fund's expenses fall below the annual rates set forth above, given that such a rate is not greater than the rate that was in place at the time of the waiver, provided, however, that the Global Fund is not obligated to pay any such reimbursed fees more than three years after the expense was incurred by Global Advisors.

Sub-Advisory services are provided to the Global Fund, pursuant to an agreement between Global Advisors and EntrepreneurShares, LLC. Under the terms of this sub-advisory agreement, Seaport Global Advisors, LLC, not the Global Fund, compensates the Sub-Advisor based on the Global Fund's average net assets. Certain officers of Seaport Global Advisors, LLC are also officers of the Sub-Advisor. Dr. Shulman is a majority owner of both Global Advisors and the Sub-Advisor. For the six months ended December 31, 2023, Global Advisors earned a fee of \$219,604 from the Global Fund.

#### US Small Cap Fund Investment Advisory Agreement

Capital Impact Advisors, LLC, a related party of the US Small Cap Fund, oversees the performance of the US Small Cap Fund is responsible for overseeing the management of the investment portfolio of the US Small Cap Fund. These services are provided under the terms of investment advisory agreements between the Trust and the Advisor, pursuant to which the Advisor receives an annual advisory fee equal to 0.75% of the US Small Cap Fund's average net assets, computed daily and paid monthly. For the six months ended December 31, 2023, Capital Impact Advisors, LLC earned \$280,831 from the US Small Cap Fund.

### **NOTES TO FINANCIAL STATEMENTS (Continued)** December 31, 2023 (Unaudited)

Through November 1, 2024 for the US Small Cap Fund, the Advisor has agreed to waive and/or reimburse the US Small Cap Fund for its advisory fee, and to the extent necessary, bear other expenses, to limit the total annualized expenses (excluding borrowing and investment-related costs and fees, taxes, extraordinary expenses and fees and expenses of underlying funds) of the Institutional Class shares of the US Small Cap Fund to the amounts of 0.85% per annum of net assets attributable to such shares of the US Small Cap Fund. The Advisor shall be permitted to recover expenses it has borne subsequent to the effective date of this agreement (whether through reduction of its advisory fee or otherwise) in later periods to the extent that the US Small Cap Fund Fund's expenses fall below the annual rates set forth above, given that such a rate is not greater than the rate that was in place at the time of the waiver, provided, however, that the US Small Cap Fund is not obligated to pay any such reimbursed fees more than three years after the expense was incurred by Advisor.

Each waiver/expense payment by the Advisor is subject to recoupment by the Advisor from the applicable Fund in the three years following the date the particular waiver/ expense payment occurred, but only if such recoupment can be achieved without exceeding the annual expense limitation in effect at the time of the waiver/expense payment and any expense limitation in effect at the time of the recoupment. The amounts subject to repayment by the Funds, pursuant to the aforementioned conditions are as follows:

Recoverable Through	Global Fund	US Small Cap Fund
June 30, 2024	\$ —	\$ 21,655
June 30, 2025	67,805	33,211
June 30, 2026	86,600	85,280
December 31, 2026	40,325	40,917

#### 4. INCOME TAXES

The Funds plan to distribute substantially all of the net investment income and net realized gains that they have realized on the sale of securities. These income and gains distributions will generally be paid once each year, on or before December 31. The character of distributions made during the year for financial reporting purposes may differ from the characterization for federal income tax purposes due to differences in the recognition of income, expense or gain items for financial reporting and tax reporting purposes.

The Fund's did not have any distributions for the fiscal year ended June 30, 2023.

The Funds designate long-term capital gain dividends, pursuant to Internal Revenue Code Section 852(b)(3), the amount necessary to reduce the earnings and profits for the Fund related to net capital gains to zero for the tax year ended June 30, 2023.

Additionally, U.S. GAAP requires that certain components of net assets be reclassified between financial and tax reporting. These reclassifications have no effect on net assets or net asset value per share.

### **NOTES TO FINANCIAL STATEMENTS (Continued)** December 31, 2023 (Unaudited)

At December 31, 2023, the net unrealized appreciation (depreciation) and tax cost of investments for tax purposes was as follows:

		US Small
	<b>Global Fund</b>	Cap Fund
Gross unrealized appreciation	\$ 7,842,096	\$ 13,844,574
Gross unrealized depreciation	(3,335,121)	(2,479,114)
Net unrealized appreciation on investments	4,506,975	11,365,460
Tax cost of investments	<u>\$ 47,410,225</u>	<u>\$ 64,739,640</u>

The table above may differ from the financial statements due to timing differences related to the deferral of losses primarily due to wash sales, passive foreign investment company mark-to-market, C-corp return on capital and MLP adjustments.

At June 30, 2023, the Funds' most recent fiscal year end, the components of accumulated earnings (deficit) on a tax basis were as follows:

	Global Fund	US Small Cap Fund
Undistributed ordinary income	\$ 34,997	\$
Accumulated capital and other losses	(24,807,036)	(4,429,526)
Unrealized depreciation on investments	(2,888,578)	(7,614,938)
Total accumulated deficit	<u>\$ (27,660,617)</u>	<u>\$ (12,044,464)</u>

As of June 30, 2023, the Funds' most recent fiscal year end, the Global Fund had short-term and long-term capital loss carryforwards available to offset future gains, not subject to expiration, in the amount of \$21,240,142 and \$3,566,894, respectively, and the US Small Cap Fund had short-term carryforwards available to offset future gains, not subject to expiration, in the amount of \$4,429,526.

#### 5. RELATED PARTIES

At December 31, 2023, certain officers of the Trust were also employees of the Advisors. However, these officers were not compensated directly by the Funds. Refer to Note 1 for more information.

#### 6. **BENEFICIAL OWNERSHIP**

The beneficial ownership, either directly or indirectly, of more than 25% of the voting securities of a fund creates a presumption of control of a fund, under Section 2(a)(9) of the 1940 Act. As of December 31, 2023, for the benefit of its shareholders, MAC & Co., an affiliate of Global Fund, held 95.99% of the total Global Fund shares outstanding. As of December 31, 2023, for the benefit of its shareholders, MAC & Co., an affiliate of the US Small Cap Fund, held 81.90% of the total US Small Cap Fund shares outstanding.

### NOTES TO FINANCIAL STATEMENTS (Continued) December 31, 2023 (Unaudited)

#### 7. INVESTMENT TRANSACTIONS

For the six months ended December 31, 2023, purchases and sales of investment securities, other than short-term investments, were as follows:

	Purchases	Sales
Global Fund	\$ 51,826,799	\$ 50,093,149
US Small Cap Fund	63,102,179	80,749,162

There were no purchases or sales of long-term U.S. government obligations during the six months ended December 31, 2023.

#### 8. REDEMPTION FEES

Each Fund imposes a redemption fee equal to 2% of the dollar value of the shares redeemed within five business days of the date of purchase. The redemption fee does not apply to shares purchased through reinvested distributions (dividends and capital gains) or through the automatic investment plan, shares held in retirement plans (if the plans request a waiver of the fee), or shares redeemed through designated systematic withdrawal plans.

#### 9. SECTOR RISK

If a Fund has significant investments in the securities of issuers within a particular sector, any development affecting that sector will have a greater impact on the value of the net assets of the Fund than would be the case if the Fund did not have significant investments in that sector. In addition, this may increase the risk of loss in the Fund and increase the volatility of the Fund's NAV per share. For instance, economic or market factors, regulatory changes or other developments may negatively impact all companies in a particular sector, and therefore the value of a Fund's portfolio will be adversely affected. As of December 31, 2023, the Global Fund had 34.23% of the value of its net assets invested in stocks within the Technology sector and the US Small Cap Fund had 29.54% and 37.51% of its net assets invested in stocks within the Health Care and Technology sectors, respectively.

#### **10. MARKET AND GEOPOLITICAL RISK**

The increasing interconnectivity between global economies and financial markets increases the likelihood that events or conditions in one region or financial market may adversely impact issuers in a different country, region or financial market. Securities in the Funds' portfolio may underperform due to inflation (or expectations for inflation), interest rates, global demand for particular products or resources, natural disasters, pandemics, epidemics, terrorism, regulatory events and governmental or quasi-governmental actions. The occurrence of global events similar to those in recent years, such as terrorist attacks around the world, natural disasters, social and political discord or debt crises and downgrades, among others, may result in market volatility and may have long term effects on both the U.S. and global financial markets. It is difficult to predict when similar events affecting the U.S. or global financial markets may occur, the effects that such events may have and the duration of those effects. Any such event(s) could have a significant adverse impact on the value and risk profile of the Funds' portfolio. The current novel coronavirus (COVID-19) global pandemic and the aggressive responses taken by many governments, including closing borders, restricting international and domestic travel, and the imposition of prolonged quarantines or similar restrictions, as well as the forced or voluntary closure of, or operational changes to, many retail and other businesses, has had negative impacts, and in many cases severe negative impacts, on markets worldwide. It is not known how long such impacts, or any future impacts of other significant events described above, will or would last, but there could be a prolonged period of global economic slowdown, which may impact your Fund investment. Therefore, the Funds could lose money over

### NOTES TO FINANCIAL STATEMENTS (Continued) December 31, 2023 (Unaudited)

short periods due to short-term market movements and over longer periods during more prolonged market downturns. During a general market downturn, multiple asset classes may be negatively affected. Changes in market conditions and interest rates can have the same impact on all types of securities and instruments. In times of severe market disruptions, you could lose your entire investment.

#### **11. FOREIGN INVESTMENT RISK**

The Global Fund generally invests a significant portion of its total assets in securities principally traded in markets outside the U.S. The foreign markets in which the Global Fund invests in are sometimes open on days when the New York Stock Exchange ("NYSE") is not open and the Global Fund does not calculate its NAV, and sometimes are not open on days when the NYSE is open and the Global Fund does calculate its NAV. Even on days on which both the foreign market and the NYSE are open, several hours may pass between the time when trading in the foreign market closes and the time at which the Global Fund calculates its NAV. That is generally the case for markets in Europe, Asia, Australia and other far eastern markets; the regular closing time of foreign markets in North and South America is generally the same as the closing time of the NYSE and the time at which the Global Fund calculate its NAV.

Foreign stocks, as an asset class, may underperform U.S. stocks, and foreign stocks may be more volatile than U.S. stocks. Risks relating to investment in foreign securities (including, but not limited to, depository receipts and participation certificates) include: currency exchange rate fluctuation; less available public information about the issuers of securities; less stringent regulatory standards; lack of uniform accounting, auditing and financial reporting standards; and country risk including less liquidity, high inflation rates, unfavorable economic practices and political instability. The risks of foreign investments are typically greater in emerging and less developed markets.

#### **12. SUBSEQUENT EVENTS EVALUATION**

Management of the Funds has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date at which these financial statements were issued. Based upon this evaluation, management has determined there were no items requiring adjustment of the financial statements or additional disclosure except as noted below.

### **SUMMARY OF FUND EXPENSES (Unaudited)**

As a Fund shareholder, you may incur two types of costs: (1) transaction costs and (2) ongoing costs, including management fees, distribution (12b-1) fees and other Fund expenses. These examples are intended to help you understand your ongoing costs (in dollars) of investing in each Fund and to compare these costs with the ongoing costs of investing in other funds. Each Fund's example is based on an investment of \$1,000 invested at the beginning of the period and held for the entire period from July 1, 2023 through December 31, 2023.

#### Actual Expenses

The first line of the table for each Fund class provides information about actual account values and actual expenses. You may use the information in these lines, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number in the first line under the heading "Expenses Paid During Period" to estimate the expenses you paid on your account during this period.

#### Hypothetical Example for Comparison Purposes

The second line of the table below for each class provides information about hypothetical account values and hypothetical expenses based on each Fund's actual expense ratios and an assumed rate of return of 5% per year before expenses, which is not the Fund's actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balances or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in the Fund's and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.

Expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs. Therefore, the second line of the table for each class is useful in comparing ongoing costs only and will not help you determine the relative total costs of owning different funds. In addition, if transaction costs were included, your costs would have been higher.

		Beginning Account Value July 1, 2023	Ending Account Value December 31, 2023	Expenses Paid During Period <sup>(a)</sup>	Annualized Expense Ratio
ERShares Global Entrepreneurs	Actual	\$1,000.00	\$ 1,062.60	\$ 5.08	0.98%
	Hypothetical <sup>(b)</sup>	\$1,000.00	\$ 1,020.21	\$ 4.98	0.98%
ERShares US Small Cap					
	Actual	\$1,000.00	\$ 1,040.10	\$ 4.36	0.85%
	Hypothetical <sup>(b)</sup>	\$1,000.00	\$ 1,020.86	\$ 4.32	0.85%

(a) Expenses are equal to the Fund's annualized expense ratios, multiplied by the average account value over the period, multiplied by 184/366 (to reflect the one-half year period).

<sup>(b)</sup> Hypothetical assumes 5% annual return before expenses.

### **INVESTMENT ADVISORY AGREEMENT APPROVAL (Unaudited)**

On August 23, 2023, all of the Trustees of EntrepreneurShares Series Trust (the "Trust") met to discuss, among other things, the continuation of the investment advisory agreements and a sub- advisory agreement, as applicable, for the ERShares Global Entrepreneurs (the "Global Fund"), and the ERShares US Small Cap (the "Small Cap Fund"), (collectively referred to as the "Funds"). In preparation for the meeting they reviewed materials addressing the review and consideration of the investment advisory agreements and a sub-advisory agreement, which included a Gartenberg Memo to the Board of Trustees (the "Board") from legal counsel, 15(c) analyses for the Funds, and the returns of each Fund and the Funds' benchmark indices provided in the quarterly Board materials.

Seaport Global Advisors, LLC ("Seaport") (formerly known as Weston Capital Advisors, LLC) is the Global Fund's investment adviser, and EntrepreneurShares, LLC ("EntrepreneurShares") is the Global Fund's investment sub-adviser. Capital Impact Advisors, LLC ("Capital Impact Advisors") is the investment adviser to the Small Cap Fund. Seaport, EntrepreneurShares, and Capital Impact Advisors are referred to herein as the "Advisers," and the investment advisory agreements for the Global Fund and the Small Cap Fund, along with the sub-advisory agreement for the Global Fund, are referred to herein as the "Advisory Agreements." The Advisers are responsible for management of the investment portfolio of the Funds, and for overall management of the Funds' business and affairs pursuant to the Advisory Agreements.

At the meeting, the Trustees had ample opportunity to consider matters they deemed relevant in considering the approval of the Advisory Agreements, and to request any additional information they considered reasonably necessary to their deliberations, without undue time constraints. In addition to the materials requested by the Trustees in connection with their consideration of the continuation of the Advisory Agreements, the Trustees received materials in advance of each regular quarterly meeting of the Board of Trustees that provided information relating to the services provided by the Advisers.

The Board then reviewed and discussed the written materials that were provided in advance of the Meeting and deliberated on the renewal of the Advisory Agreements. The Board relied upon the advice of independent legal counsel and their own business judgment in determining the material factors to be considered in evaluating the Advisory Agreements and the weight to be given to each such factor. The conclusions reached by the Board were based on a comprehensive evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to the various factors in reaching his conclusions with respect to the Advisory Agreements. In considering the renewal of the Advisory Agreements, the Board reviewed and analyzed various factors that they determined were relevant, including the factors enumerated below.

*Nature, Extent and Quality of Services.* The Board reviewed materials provided by Seaport, Capital Impact Advisors and EntrepreneurShares related to the proposed renewal of the Advisory Agreements with respect to the Funds, including each Form ADV and related schedules, a description of the manner in which investment decisions were made and executed, a review of the personnel performing services for each of the Funds, including the individuals that primarily monitor and execute the investment process. The Board discussed the extent of the research capabilities, the quality of the compliance infrastructure and the experience of its investment advisory personnel. The Board noted that each Adviser was an experienced investment adviser with seasoned senior management and that the performance of each Fund was supported by the quality and experience of the staff. Additionally, the Board received satisfactory responses from the representatives of each Adviser with respect to a series of important questions, including: whether each Adviser was involved in any lawsuits or pending regulatory actions; whether the advisory services provided to its other accounts would conflict with the advisory services provided to each of the Funds; whether there were procedures in place to review the portfolio managers' performance of their duties to ensure compliance under its compliance program. The Board reviewed the information provided on the practices for monitoring compliance with each of the Funds' investment limitations and discussed the compliance programs with the CCO of the Trust. The Board noted that the

### **INVESTMENT ADVISORY AGREEMENT APPROVAL (Unaudited) (Continued)**

CCO of the Trust continued to represent that the policies and procedures were reasonably designed to prevent violations of applicable federal securities laws. The Board also noted each Adviser's representation that the prospectus and statement of additional information for the Funds accurately describe the investment strategies of each of the Funds. The Board then reviewed a description of the capitalization of each Adviser based on financial information provided by and representations made by each Adviser and its representatives and concluded that each Adviser was sufficiently well-capitalized, or its principals have the ability to make additional contributions in order to meet its obligations to each of the Funds. The Board concluded that each Adviser had sufficient quality and depth of personnel, resources, investment methods and compliance policies and procedures essential to performing its duties under the respective Advisory Agreement and that the nature, overall quality and extent of the advisory services to be provided by each Adviser to each of the Funds were satisfactory.

The Board reviewed the performance, fee and expense information provided by Ultimus Fund Solutions, LLC using data provided by Morningstar, Inc. ("Morningstar"). The Board considered the limitations with such a process, including that the categorization determined by Morningstar may or may not subjectively correlate with a Fund's investment strategy or portfolio holdings. The Board noted that the historical data used in the 15(c) analyses was as of the reporting period ended June 30, 2023, and that as of that date the Global Fund and Small Cap Fund had approximately \$49.448, and \$79.904, million in net assets, respectively. The Board observed that for the fiscal year ended June 30, 2023, the Advisor contractually waived its advisory fees for the Global Fund and Small Cap Fund, for approximately \$171,880 (approximately evenly split), to reduce each Fund's expense ratio to the contractually agreed waiver.

Performance.

#### <u>Global Fund</u>

The Board discussed Morningstar's classification of the Global Fund as a World Large Stock Fund. The Board referred to the World Large Stock category analysis as of June 30, 2023, noting that the average net assets for funds in the peer category was \$90.71 million. The Board observed that the Global Fund's one-year, three-year, five-year, and ten-year annualized returns noting they generally lagged the peer group, Morningstar Category and index. However, the Board noted that while performance generally lagged the comparative references, the strategy was long-term and that it seemed imprudent to suggest that the Adviser change course.

#### <u>Small Cap Fund</u>

The Board discussed Morningstar's classification of the Small Cap Fund as a Small Cap Growth Fund. The Board referred to the Small Cap Growth category analysis as of June 30, 2023, noting that the average net assets for funds in the peer category was \$107.98 million. The Board observed that the Small Cap Fund's five-year annualized return was 2.28%, the peer group's average five- year annualized return was 5.49%, and the entire Small Cap Growth category's average five-year annualized return was 6.69%. The Board reviewed the Fund's one-year, three-year, and five-year annualized returns noting they had generally lagged the peer group, Morningstar Category and indexes, but that the one-year returns revealed a significant recovery of the strategy as the one-year returns significantly outperformed the comparative references. Here too, the Board noted the strategy was long-term and that it seemed imprudent to suggest that the Adviser change course.

*Fees and Expenses.* The Board reviewed the fee and expense information provided by the Advisers. The Board considered the limitations with such a process, including that the categorization determined by Morningstar may or may not subjectively correlate with a Fund's investment strategy or portfolio holdings. The Board noted that the historical data used in the 15(c) analyses was as of the reporting period ended June 30, 2023. The Board observed that for the

### **INVESTMENT ADVISORY AGREEMENT APPROVAL (Unaudited) (Continued)**

fiscal year ended June 30, 2023, the Advisor contractually waived its advisory fees for the Global Fund and Small Cap Fund for approximately \$171,880 (approximately evenly split), to reduce each Fund's expense ratio to the contractually agreed waiver.

#### <u>Global Fund</u>

The Board noted that the Global Fund's management fee of 0.89% was greater than the peer group's average management fee of 0.75%, the net expense ratio of 0.99% was less than the peer group's average net expense ratio of 1.36%; and that the Fund's management fee and expenses were within the reasonable range of fees as compared to its peers.

#### <u>Small Cap Fund</u>

The Board noted that the Small Cap Fund's management fee of 0.75% was just above the peer group's average management fee of 0.71%, and the Small Cap Fund's net expense ratio of 0.86% was less than the peer group's average net expense ratio of 0.96%.

The Board consider each Adviser's unique entrepreneurial investment approach and the resources required to implement and maintain such an approach with respect to management of the Funds. The Board concluded that the fee charged by the Advisers to the Funds was not unreasonable.

*Profitability.* The Board reviewed a profitability summary representation that was provided by the Advisers, indicating that profits, if any, were below the 50% margin. They noted that the Funds' annual and semi-annual shareholder reports, which contained audited financial statements including gross revenues earned by each Adviser with respect to its management of a respective Fund along with any applicable waived fees and expenses of each Fund. They noted that while each Adviser earned a profit with respect to its management of the Funds, the profit return did not appear to be excessive.

*Economies of Scale.* The Board examined the Adviser's effort to achieve economies of scale for each Fund to the benefit of each Fund's respective shareholders. The Board determined that as the Funds' assets increase, economies of scale could be realized and will be revisited later.

#### **Conclusion**

The Board weighed all of the factors presented to them in the Gartenburg Memo, the Morningstar analysis of returns and expense ratios, the returns of the benchmark indices, profitability analysis and discussions with the Advisers during the Board meeting to consider the renewal of the Advisory Agreements. Without paying particular weight to any one factor, the Board, including a majority of the Independent Trustees, determined the advisory fees were fair and not unreasonable for the services provided and it was in the best interest of shareholders to continue the Advisory Agreements for a one-year period.

### ADDITIONAL INFORMATION (Unaudited)

### AVAILABILITY OF QUARTERLY PORTFOLIO HOLDINGS SCHEDULES

The Funds file complete schedules of portfolio holdings with the SEC for the first and third quarters of each fiscal year on Form N-PORT (or any predecessor form). These filings are available on the SEC's website at www.sec.gov. In addition, the Funds' Form N-PORT is available without charge, upon request, by calling 1-877-271-8811.

#### PROXY VOTING POLICIES AND PROCEDURES AND PROXY VOTING RECORD

A description of the Funds' proxy voting policies and procedures and information regarding how the Funds voted proxies relating to portfolio securities during the most recent 12 month period ended June 30, is available without charge, upon request, by (1) calling 1-877-271-8811, or (2) on the SEC's website at www.sec.gov.

#### HOUSEHOLDING

To reduce expenses, each Fund generally mails only one copy of its prospectus and each annual and semi-annual report to those addresses shared by two or more accounts and to shareholders that such Fund reasonably believes are from the same family and household. This is referred to as "householding." If you wish to discontinue householding and would like to receive individual copies of these documents, please call us at 1-877-271-8811. Once a Fund receives notice to stop householding, the Fund will begin sending individual copies 30 days after receiving requests. This policy does not apply to account statements.

### **PRIVACY POLICY (Unaudited)**

As part of the EntrepreneurShares fund family's long tradition of trust, the confidentiality of personal information is paramount. We maintain high standards to safeguard your personal information. We will remain vigilant and professional in protecting that information and in using it in a fair and lawful manner. As part of this commitment to fulfilling your trust we have formulated this Privacy Policy.

#### Safeguarding Customer Information and Documents

To conduct regular business, we may collect nonpublic personal information from sources such as:

- Account Applications and other forms, which may include a customer's name, address, social security number, and information about a customer's investment goals and risk tolerances;
- Account History, including information about the transactions and balances in a customer's account; and
- Correspondence, written, telephonic, or electronic between a customer and Seaport Global Advisors, LLC; Capital Impact Advisors, LLC; EntrepreneurShares, LLC, and/or any EntrepreneurShares Mutual Fund or Exchange-Traded Fund product; such as, ERShares Global Fund, ERShares US Small Cap, ERShares Entrepreneurs ETF, ERShares NextGen Entrepreneurs ETF, or service providers to Seaport Global Advisors, Capital Impact, EntrepreneurShares, and/or EntrepreneurShares' Funds.

To conduct regular business, we collect non-public customer data in checklists, forms, in written notations, and in documentation provided to us by our customers for evaluation, registration, licensing or related consulting services. We also create internal lists of such data.

EntrepreneurShares will internally safeguard your nonpublic personal information by restricting access to only those employees who provide products or services to you or those who need access to your information to service your account. In addition, we will maintain physical, electronic and procedural safeguards that meet federal and/or state standards to guard your nonpublic personal information. Failure to observe EntrepreneurShares' procedures regarding customer and consumer privacy will result in discipline and may lead to termination.

#### Sharing Nonpublic Personal and Financial Information

As EntrepreneurShares shares nonpublic information solely to service our client accounts, we do not disclose any nonpublic personal information about our customers or former customers to anyone, except as permitted by law or otherwise disclosed herein.

EntrepreneurShares is committed to the privacy and protection of our customers' personal and financial information. We will not share any such information with any affiliated or nonaffiliated third party except:

- When necessary to complete transactions in a customer account, such as clearing firm.
- When required to service and/or maintain your account.
- In order to resolve a customer dispute or inquiry.
- With persons acting in a fiduciary or representative capacity on behalf of the customer.
- With rating agencies, persons assessing compliance with industry standards, or to the attorneys, accountants and auditors of the firm.
- In connection with any sale and / or merger of EntrepreneurShares' business.
- To prevent or protect against actual or potential fraud, identity theft, unauthorized transactions, claims or other liability.
- To comply with all federal, state or local laws, rules, statutes and other applicable legal requirements.

### **PRIVACY POLICY (Unaudited) (Continued)**

- In connection with a written agreement to provide advisory services or investment management when the information is released solely for the purpose of providing products or services covered by pursuant to the EntrepreneurShares' Wrap Fee Program.
- Upon the customer's specific instruction, consent or request.

Note: When we share your nonpublic information with any third party for the reasons listed above, we make certain that there are written restrictions in place regarding the use and/or disclosure of said information.

#### **Opt-Out Provisions**

It is not a policy of EntrepreneurShares to share nonpublic personal and financial information with affiliated or unaffiliated third parties except under the circumstances noted above. Since sharing under the circumstances noted above is necessary to service customer accounts or is mandated by law, there are no allowances made for clients to opt out.

This page intentionally left blank.

#### **ERShares Global Entrepreneurs Investment Advisor**

Seaport Global Advisors, LLC 175 Federal Street, Suite 875 Boston, MA 02110

#### **ERShares Global Entrepreneurs Investment Sub-Advisor**

EntrepreneurShares, LLC 175 Federal Street, Suite 875 Boston, MA 02110

#### **ERShares US Small Cap Investment Advisor**

Capital Impact Advisors, LLC 175 Federal Street, Suite 875 Boston, MA 02110

#### **Independent Registered Public Accounting Firm**

Cohen & Company, Ltd. 1835 Market Street, Suite 310 Philadelphia, PA 19103

#### Custodian

UMB Bank, N.A. 928 Grand Boulevard, 5th Floor Kansas City, MO 64106

#### Distributor

Vigilant Distributors, LLC 223 Wilmington West Chester Pike, Suite 216 Chadds Ford, PA 19317

#### Administrator, Accountant, Transfer Agent and Dividend Disbursing Agent

Ultimus Fund Solutions, LLC 225 Pictoria Drive, Cincinnati, OH 45246

#### Counsel

*Thompson Hine LLP* 41 South High Street, Suite 1700 Columbus, OH 43215

This report should be accompanied or preceded by a prospectus.